Moderna Stock News

A new, potentially more contagious variant of the coronavirus is already circulating in Europe. A number of countries have banned the entry of passengers from southern Africa, where the Omicron variant was found, in the past two days. Britain, Germany, Italy and the Czech Republic yesterday identified the first cases of people infected with this variant and announced new measures to control the infection. Fears of the new variant and the potential for it to be more resistant to the protection provided by vaccines are raising concerns that the pandemic and related lockdowns and restrictions may last longer than expected. Nearly two years after the start of the pandemic, which claimed the lives of more than 5 million people globally, countries around the world are on the alert. On Friday, a number of countries banned flights from South Africa and neighboring countries to allow time to assess whether this option is more contagious than the currently dominant Delta option. The Republic of South Africa regretted the closure of the borders of dozens of countries for its citizens and travelers and said that the discovery of the new version of Omicron coronavirus thanks to the work of South African scientists should not be "punished" in this way. "This latest series of travel bans is actually punishing South Africa for its progress in genomic sequencing and its ability to discover new variants more quickly.

Bang Sue Grand Station Vaccination Center announced that from November 26, the center will only offer Pfizer and Moderna jabs as 1st, 2nd and 3rd doses, depending on what is available on the day. Those who insist on receiving the AstraZeneca and Sinovac vaccines must make a request before the appointment day. Teenagers aged 12 []

An outlier in the U.S. pharmaceutical industrys vaccine wars, one which uses a totally different technology than the current gene therapy vaccines sold by Moderna, Pfizer, and Johnson & Johnson, says it will have a vaccine ready for testing and manufacturing ready in the next several weeks, according to reports. Novavax was paraphrased by Reuters []

The new potentially more contagious omicron variant of the coronavirus popped up in more European countries on Saturday, just days after being identified in South Africa, leaving governments around the world scrambling to stop the spread. The U.K. on Saturday tightened its rules on mask-wearing and on testing of international arrivals after finding two cases. New cases were confirmed Saturday in Germany and Italy, with Belgium, Israel and Hong Kong also reporting that the variant has been found in travellers. In the U.S., Dr. Anthony Fauci, the governments top infectious diseases expert, said he would not be surprised if the omicron variant was already in the United States, too. We have not detected it yet, but when you have a virus that is showing this degree of transmissibility it almost invariably is ultimately going to go essentially all over, Fauci said on NBC television. Because of fears that the new variant has the potential to be more resistant to the protection offered by vaccines, there are growing concerns around the world that the pandemic and associated lockdown restrictions will persist for far longer than hoped.

A new strain of COVID-19 first discovered in South Africa was declared a variant of concern by the World Health Organization on Friday. Here''s how the pharmaceutical industry plans to address the latest coronavirus curve ball. Vaccine makers are already pivoting their efforts to combat the new variant: testing higher doses of booster shots, designing new boosters that anticipate strain mutations, and developing omicron-specific boosters. In a statement sent to NPR, Moderna said it has been working on a comprehensive strategy to predict variants of concern since the beginning of 2021. One approach is to double the current booster from 50 to 100 micrograms. Secondly, the vaccine maker has been studying two booster vaccines that are designed to anticipate mutations like those found in the omicron variant. The company also said it will ramp up efforts to make a booster candidate that specifically targets omicron. "From the beginning, we have said that as we seek to defeat the pandemic, it is imperative that we are proactive as the virus evolves," said Moderna CEO Stéphane Bancel. "The mutations in the Omicron variant are concerning and for several days, we have been moving as fast as possible to execute our strategy to address this variant." Pfizer and BioNTech told Reuters that it expects more data about the omicron variant to be collected within two weeks.

Hungarian FM Peter Szijjarto told RT he''s ?frustrated? with Western officials playing politics with Russia''s Sputnik V, world''s first registered Covid vaccine. He says they can?t bring themselves to admit publicly it''s ?the best.? The European Medicines Agency (EMA) has approved vaccines by Pfizer, Moderna, AstraZeneca, and Janssen, yet Russia''s Sputnik V is still awaiting the agency''s nod despit

Hungarian FM Peter Szijjarto told RT he''s ?frustrated? with Western officials playing politics with Russia''s Sputnik V, world''s first registered Covid vaccine. He says they can?t bring themselves to admit publicly it''s ?the best.? The European Medicines Agency (EMA) has approved vaccines by Pfizer, Moderna, AstraZeneca, and Janssen, yet Russia''s Sputnik V is still awaiting the agency''s nod despit

The manufacturers of Americas most used COVID-19 vaccines insist they have plans in place to quickly adapt to potential challenges presented by the new omicron variant.

Moderna to Test Variant-Specific Vaccine Candidate Morningstar.com

The main manufacturers of vaccines against COVID-19 In the West, including Americans Pfizer, Moderna and Johnson & Johnson, reported Friday that they are already testing

PFIZER and Moderna are reportedly capable of updating their COVID-19 vaccines as the new Omicron strain has sparked fear across the world.

Moderna Inc (MRNA) shares closed today 20.6% higher than it did at the end of yesterday. The stock is currently up 215.5% year-to-date, up 201.9% over the past 12 months, and up 1672.2% over the past five years. Today, the Dow Jones Industrial Average fell 2.5%, and the S&P 500 fell 2.2%. Trading Activity Shares traded as high as $350.15 and as low as $258.09 this week.Shares closed 33.7% below its 52-week high and 221.1% above its 52-week low.Trading volume this week was 66.2% lower than the 10-day average and 64.6% lower than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.0. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price beats the S&P 500 Index today, beats it on a 1-year basis, and beats it on a 5-year basis The company's share price beats the Dow Jones Industrial Average today, beats it on a 1-year basis, and beats it on a 5-year basis The company share price beats the performance of its peers in the Health Care industry sector today, beats it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -23420.1% The company's stock price performance over the past 12 months beats the peer average by 2054.9% The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is 377.0% higher than the average peer. This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

THE HAGUE: The European Union''s drug regulator said on Friday (Saturday in Manila) that it was closely monitoring the new B.1.1.529 Covid-19 variant, but it was too soon to tell if updated vaccines would be needed. The European Medicines Agency (EMA) said it needed more details to see if the strain, which has "numerous mutations," could evade the current four jabs authorized for the bloc. "We are closely monitoring the newly emerged B.1.1.529 variant which presents numerous mutations in the Covid-19 spike protein," the Amsterdam-based EMA said in a statement to Agence France-Presse. "Current information is insufficient to determine if this variant is going to spread significantly and to what extent it may evade the immunity received with vaccines." It added: "EMA considers it premature at the moment to foresee the need of an adapted vaccine with a different composition in order to tackle this emerging variant." The EU has reacted with concern to news of the new strain, proposing that member states stop all flights to and from southern African where it was first discovered.